Corinne Johnson
Stock Analyst at Goldman Sachs
(2.86)
# 1,842
Out of 5,036 analysts
14
Total ratings
46.15%
Success rate
12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $15.37 | +30.12% | 2 | Sep 16, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $20 → $24 | $15.57 | +54.14% | 2 | Sep 5, 2025 | |
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $49.01 | +12.22% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $19.99 | +65.08% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $141.33 | +28.78% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $43.59 | +14.71% | 3 | May 14, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $19.22 | +160.15% | 1 | Mar 13, 2024 |
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $15.37
Upside: +30.12%
Syndax Pharmaceuticals
Sep 5, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $15.57
Upside: +54.14%
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $49.01
Upside: +12.22%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $19.99
Upside: +65.08%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $141.33
Upside: +28.78%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $43.59
Upside: +14.71%
Immunovant
Mar 13, 2024
Initiates: Buy
Price Target: $50
Current: $19.22
Upside: +160.15%